Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ced 2008 mipomersen development plan with Genzyme

-- Reported preclinical study in Circulation showing that mipomersen

lowers Lp(a) and oxidized-LDL, independent risk factors for

cardiovascular disease

-- Initiated Phase 3 study in heterozygous FH subjects with coronary

artery disease

-- Granted broad patent coverage for antisense compounds targeting

apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense

modulation of Apolipoprotein B Expression"

Metabolic Program

-- Highlighted our robust diabetes and obesity portfolio with nine

presentations and posters at the American Diabetes Association meeting

-- Presented new preclinical data relating to ISIS 388626, Isis' drug

targeting SGLT2

-- Presented results from eight research programs on novel targets

that offer new mechanisms to address metabolic diseases, including

obesity

Other Partnered Programs

-- ATL and Teva reported encouraging Phase 2 results for ATL/TV1102,

targeting VLA-4 in patients with multiple sclerosis

-- Partnered oncology drugs highlighted at the American Society of

Clinical Oncology demonstrate the potential of antisense technology to

treat multiple cancers

-- OncoGenex reported encouraging Phase 2 results on OGX-011,

targeting clusterin, in patients with hormone refractory prostate

cancer

-- Eli Lilly and Company reported positive Phase 1 clinical trial

results for LY2181308, targeting survivin

-- Atlantic Healthcare received U.S. orphan drug designation for

alicaforsen for the treatment of pouchitis

-- Altair Therapeutics advanced AIR 645 into Phase 1 studies for the

treatment of asthma

Regulus Therapeutics (microRNA Joint Venture)

-- Entered into strategic alliance wit
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DIEGO and TORONTO , ... APTO ; TSX: APS), a clinical-stage company developing new ... announced that the U.S. Food and Drug Administration (FDA) ... for the treatment of acute myeloid leukemia (AML). APTO-253, ... company,s lead product candidate in a Phase Ib clinical ...
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... Pa. , June 2, 2015   ... be attending the BIO Exhibition 2015 in ... Exhibition, the world,s largest biotechnology gathering, allows influential ... high-level executives, where they can evaluate emerging technologies ... significant eClinical expertise in the design, implementation and ...
(Date:6/2/2015)... Mass. , June 2, 2015 /PRNewswire/ ... a biotechnology company focused on discovering and ... of dermatology and ophthalmology, today announced that Dr. ... Officer, will present at the 23 rd ... six-day world congress will include in-depth presentations ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4
... BioCryst,Pharmaceuticals (Nasdaq: BCRX ) today announced ... Chief Medical Officer of BioCryst, effective July 1,2008. ... recently,serving as Vice President of North American Medical ... Officer Dr. Tom Simon, who has been with,the ...
... use Nuevolution,s Chemetics(R) Technology for Lead Discovery, ... it has entered into a drug discovery collaboration ... its proprietary Chemetics(R) drug discovery,technology to identify novel ... to Merck. The Chemetics(R) platform uses innovative DNA,labeling ...
... Pa., June 17 MEDRAD, INC., announced ... a new Fluorodeoxyglucose (FDG),Infusion System for Positron ... Intego(TM) PET Infusion System is the,first infusion ... automate the FDG,delivery process., (Logo: ...
Cached Biology Technology:William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 2William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 3William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 4Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3
(Date:5/6/2015)... LifeBEAM, a developer of bio-sensing technology, and ... that they will expand their partnership in bio-sensing sports ... helmet and the first joint project between the two ... order to give cyclists more style choices and meet ... Lazer announced their plan to release a new generation ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... researchers in Switzerland has published a study appearing in the ... that shows how the cornea uses stem cells to ... everyday wear and tear on the cornea is repaired from ... serious repair jobs require the involvement of other stem cells ...
... (NorthShore) and Northwestern University have discovered that fiber optic ... blood levels in the colonic lining (mucosa) in humans, ... cancer. The study appears in the October ... of the American Gastroenterological Association (AGA) Institute. ...
... is a primary concern for agricultural producers in the United ... effort to maintain a profitable crop output. , ... while it is known that using nitrogen fertilizers can increase ... following cash crops have been unknown. Researchers found ...
Cached Biology News:The role of stem cells in renewing the cornea 2Breakthrough optical technology to assess colon cancer risk, accuracy 2Breakthrough optical technology to assess colon cancer risk, accuracy 3Nitrogen applied 2
...
A component of the Acridinium protein labeling kit....
... detection system holds 48 x 0.2 ml tubes, ... LEDs independently excites fluorescence (470-500 nm) for each ... emitted light (523-543 nm and 540-700 nm). The ... whose Peltier heat pumps provide superb thermal performance. ...
... Automated instrument designed to hold up to ... The robust and easy to use design ensures ... with regular cyclic stretching or compression. This unit ... of the strain to produce 64 unique strain ...
Biology Products: